AllRest Pitchdeck 1.04

ALLREST TECHNOLOGIES LLC

Pitchdeck Presentation:Juan Ramon Zarco,

President/[email protected]

(703) 376-4893

2

HIGHLY CONFIDENTIAL AND PRIVILEGED INFORMATION

The information contained herein is being furnished on a confidential basis. AllRest Technologies LLC (the “Company”) expects it to be used for the sole purpose of considering an interest in atransaction with the Company. BY RECEIPT OF THE ENCLOSED MATERIALS, THE RECIPIENT AGREES THAT THE INFORMATION CONTAINED HEREIN WILL BE KEPTCONFIDENTIAL AND SHALL NOT, WITHOUT PRIOR WRITTEN CONSENT FROM THE COMPANY BE DISCLOSED BY THE RECIPIENT IN ANY MANNER WHATSOEVER INWHOLE OR IN PART, AND SHALL NOT BE USED OTHER THAN IN CONNECTION WITH THE TRANSACTION DESCRIBED HEREIN. The recipient shall be responsible for anybreach of this confidentiality undertaking by its agents, employees, or representatives. Moreover, the recipient shall agree to transmit the information only to its agents, employees, andrepresentatives who need to know the information for the purpose of evaluating the materials herein, who are informed of the confidential nature of the information and who agree to maintain itsconfidentiality. Should the recipient decline to acquire an interest in any transaction with the Company, it shall return all supplied materials as soon as possible and, in any event, upon request,and continue to maintain in confidence any memoranda or similar materials prepared by or for the benefit of the recipient based upon the materials supplied to it.

THE ENCLOSED MATERIALS SHALL NOT BE PHOTOCOPIED, REPRODUCED, OR DISTRIBUTED TO OTHERS AT ANY TIME WITHOUT PRIOR WRITTENCONSENT OF THE COMPANY.

Contact:Rob de Heer or Juan Ramon Zarco

(408) 316-1976 (703) 376-4893

AllRest Technologies LLCPO Box 60123

Palo Alto, CA 94306(408) 316-1976

OVERVIEW• AlllRest designs and markets cost effective, smart,

therapeutic medical devices for sleep disorders

• U.S. Total Addressable Market (TAM) is 53 million users

• Current working prototype has been developedsince 2009 and has been effective in private trials

• New electronic technologies will allow CRMmonitoring of the medical device’s performanceand adjust the device for maximum efficiency

• EBITDA Margins exceed 78% in this space

• AllRest seeks $1.5 million to complete electronics, tohandle regulatory matters, and to market the devicein the U.S. and Worldwide

AllrestTech.com Private & Confidential 20143

THE PROBLEM• The predominant therapy is the

Continuous Positive Air Pressure(CPAP), the current legacy devicein treating sleep-disorderedbreathing.

• 17% - 40% of CPAP patientsabandon the device after severalmonths – discomfort, costs

• CPAP equipment costs $500-$5,000

• Other sleep disorder solutionsinclude surgery, dentallyprescribed mouthpieces-$1,500,and electrical implants – allphysically invasive and costly

• Over 53 million people suffer fromsome sleep disorder. 20% areuntreated. And about 10% areuninsured.


SOLUTION – OPTI-FLOW

• TheAllRest medical device, Opti-Flow, an alternative to CPAP, is anadvanced technology to be usedeasily with the least amount ofsleep discomfort

• Filters can be replaced to fit theindividual’s apnea needs andperformance

• Sensors and data can provideweekly sleep reports for CRM

• By integrating the medical devicewith a health platform, the usercan monitor his/her weight or anyother conditions for better sleepregimen

• Priced at or below $200, thedevice is economically availableto those with or without insurancecoverage

• It improves the Sleep Apnea Indexby 40% at a fraction of a CPAP


MARKET OPPORTUNITY AND DRIVERS Current U.S. TAM is 53 million users Rest Of the World is still catching up to Sleep Disorder recognition and

treatment It is estimated that less than 20% of those with Obstructive Sleep Apnea

have not been diagnosed or treated, about 10 million. Over 8 millionapnea sufferers without medical coverage

According to a report by the global research firm MarketsandMarkets,the global sleep apnea device market, which was valued at more than$7 billion last year, is expected to increase to $19.72 billion by 2017

Potential worldwide growth: A recent report from July 2013 showed thatthe US passed on the obesity rates leadership to Mexico, moving intosecond place for the most obese nation. Researchers estimate thatBrazil will trail the US in 2022, with 64 million overweight and 26 millionobese.

According to the report, nearly 2.8 million people worldwide die eachyear as a result of obesity and the conditions it causes, which includesthe potential for sleep apnea

Worldwide TAM will be about 400 million


MARKETING STRATEGY

AllRest will target sales of 1.1 million units in 3 years, within the U.S.53 million TAM with a growing OSA market

The Opti-Flow medical device will be priced at or about $200, lessthan 50% of the least cost CPAP

AllRest will implement the “shock and awe” marketing to useeCommerce and the 1-800-AllRest support to the product

AllRest will distribute the medical device in Europe and LatinAmerica where the regulatory hurdles are fewer, and thenpenetrate the U.S.

AllRest will use digital ad agencies to market the product in themedia to saturate the market


POTENTIAL CHANNELS/PARTNERS/RESELLERS

mHealthAlert, a European mHealth platform, already usesBluetooth to connect ECG, weight scales, blood pressure,and other remote devices to monitor health electronically

CPAP machine manufacturers and distributors (ProAct) oral appliance manufacturers sleep product stores sleep labs.


BARRIERS TO ENTRY

FDA approval processProvisional patent Integration and design of semiconductorsMarket recognition – within radarCurrent users wed to CPAP solutions.


MANAGEMENT TEAM

Juan Ramon Zarco, JD/MBA (startups: Viatel, DataFoundation/Pegasus, US Cable)

Robert de Heer (inventor, technology, software) Dr. Jerome Hester, Chief Advisor and Industry Apnea

Expert (www.calsleep.com)Marc Papageorge, Mems/Semiconductor Advisor Hogan Lovells (D.C.) – IP Legal Counsel Bank of the West



DIRECT AND INDIRECT COMPETITION

AllRest (mouth)

Fisher & Paykel

RespiratoryTherapy

Programs

CareFusion

Com

patib

ility

Scalability

Resmed

Respironics

Medtronics

• Resmed andRespironicscontrol over70% of CPAPMarket

• Resmed 2013Income $1.5bill.

• Respironics(Philips) 2013Income $1.05bill.

Clinics/Sleep lab

Provent (Nasal)


REVENUE MODEL


2014 2015 2016 2017 2018Revenue $0.0 $3,575.8 $219,317.5 $348,750.0 $426,600.0COGS 0.0 856.5 37,272.1 42,140.0 51,891.0 Total Operating Expenses 423.9 3,576.0 23,626.6 35,678.3 42,664.8EBITDA (377.2) (856.8) 158,418.8 270,931.7 332,044.2

($50,000.0)

$0.0

$50,000.0

$100,000.0

$150,000.0

$200,000.0

$250,000.0

$300,000.0

$350,000.0

$400,000.0

$450,000.0

Dolla

rs ('

000s

)

AllRest Technologies LLCProForma


Mouthpiece Prototypes Design Phases and Costs

Prototype Versions 1

Each Prototype Locations

OptiFlow01 USA

OptiFlow02UK/Mexico/NewZealand

Developmental Stages per Month/2014 Initial

September Design

OctoberDevelopment &Engineering

NovemberDevelopment &Engineering

December Programming

January Prototype

FebruaryReliability &Testing

March Beta Testing

April Integration

May

Testing andRegulatoryAcceptance

JuneCommercialProduct

TIMELINE

SUMMARY

AllRest enters into a huge Market opportunity withEBITDA margins over 78%, 1.1 million units in 2 years

Unique medical device product embedded withsmart electronics, an alternative to CPAPs

Barriers to entry – FDA approvals, Patents Seeking $1.5 mill. at pre-money of $4.5 mill.Potential exits are acquisition or IPO


ALLREST TECHNOLOGIES LLC

Juan Ramon Zarco,President/[email protected](703) 376-4893

Thank you!

Documents

AllRest Pitchdeck 1.04